FATE THERAPEUTICS INC Stock Issued During Period, Value, Stock Options Exercised
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- FATE THERAPEUTICS INC stock issued during period, value, stock options exercised for the quarter ending 2026-06-30 was $412.00K, a 50.48% decline year-over-year.
- FATE THERAPEUTICS INC stock issued during period, value, stock options exercised for the quarter ending 2025-06-30 was $832.00K, a 20700.00% increase year-over-year.
- FATE THERAPEUTICS INC stock issued during period, value, stock options exercised for the quarter ending 2024-06-30 was $4.00K, a 95.06% decline year-over-year.
- FATE THERAPEUTICS INC stock issued during period, value, stock options exercised for the quarter ending 2024-03-31 was $299.00K, a 34.68% increase year-over-year.
- FATE THERAPEUTICS INC stock issued during period, value, stock options exercised for fiscal 2024 was $295.00K, a 288.16% increase from fiscal 2023.
- FATE THERAPEUTICS INC stock issued during period, value, stock options exercised for fiscal 2023 was $76.00K, a 99.17% decline from fiscal 2022.
- FATE THERAPEUTICS INC stock issued during period, value, stock options exercised for fiscal 2022 was $9.18M, a 55.71% decline from fiscal 2021.
- FATE THERAPEUTICS INC stock issued during period, value, stock options exercised for fiscal 2021 was $20.73M, a 116.34% increase from fiscal 2020.
| Period end | Stock Issued During Period, Value, Stock Options Exercised 3 month | Stock Issued During Period, Value, Stock Options Exercised 12 month |
|---|---|---|
| 2026-06-30 | $412.00K 10-Q · filed 2026-08-13 | |
| 2025-06-30 | $832.00K 10-Q · filed 2025-11-13 | |
| 2024-12-31 | $295.00K 10-K · filed 2026-02-26 | |
| 2024-06-30 | $4.00K 10-Q · filed 2025-11-13 | |
| 2024-03-31 | $299.00K 10-Q · filed 2025-11-13 | |
| 2023-12-31 | $76.00K 10-K · filed 2025-03-05 | |
| 2023-06-30 | $81.00K 10-Q · filed 2024-11-12 | |
| 2023-03-31 | $222.00K 10-Q · filed 2024-11-12 | |
| 2022-12-31 | $9.18M 10-K · filed 2024-02-26 | |
| 2022-09-30 | $1.49M 10-Q · filed 2023-11-08 | |
| 2022-06-30 | $3.18M 10-Q · filed 2023-11-08 | |
| 2022-03-31 | $3.00M 10-Q · filed 2023-11-08 | |
| 2021-12-31 | $20.73M 10-K · filed 2023-02-28 | |
| 2021-09-30 | $8.02M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | $3.68M 10-Q · filed 2022-11-03 | |
| 2021-03-31 | $5.65M 10-Q · filed 2022-11-03 | |
| 2020-12-31 | $9.58M 10-K · filed 2023-02-28 | |
| 2020-09-30 | $1.41M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | $2.55M 10-Q · filed 2021-11-04 | |
| 2020-03-31 | $949.00K 10-Q · filed 2021-11-04 | |
| 2019-12-31 | $2.60M 10-K · filed 2022-02-28 | |
| 2019-09-30 | $163.00K 10-Q · filed 2020-11-05 | |
| 2019-06-30 | $688.00K 10-Q · filed 2020-11-05 | |
| 2019-03-31 | $1.26M 10-Q · filed 2020-11-05 | |
| 2018-12-31 | $2.69M 10-K · filed 2021-02-24 | |
| 2018-09-30 | $1.13M 10-Q · filed 2019-11-05 | |
| 2018-06-30 | $175.00K 10-Q · filed 2019-11-05 | |
| 2018-03-31 | $606.00K 10-Q · filed 2019-11-05 | |
| 2017-12-31 | $226.00K 10-K · filed 2020-03-02 | |
| 2017-09-30 | $119.00K 10-Q · filed 2018-11-01 | |
| 2017-06-30 | $32.00K 10-Q · filed 2018-11-01 | |
| 2017-03-31 | $35.00K 10-Q · filed 2018-11-01 | |
| 2016-12-31 | $187.00K 10-K · filed 2019-03-05 | |
| 2015-12-31 | $420.00K 10-K · filed 2018-03-05 | |
| 2014-12-31 | $142.00K 10-K · filed 2017-03-16 | |
| 2013-12-31 | $23.00K 10-K · filed 2016-03-03 | |
| 2012-12-31 | $15.00K 10-K · filed 2015-03-12 | |
| 2011-12-31 | $14.00K 10-K · filed 2014-03-17 | |
| 2010-12-31 | $10.00K 10-K · filed 2014-03-17 | |
| 2009-12-31 | $21.00K 10-K · filed 2014-03-17 | |
| 2008-12-31 | $1.00K 10-K · filed 2014-03-17 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Liminatus Pharma, Inc. (LIMN) | United States | $0.282B | |
| Lexeo Therapeutics, Inc. (LXEO) | United States | $0.278B | -4.19 |
| PALISADE BIO, INC. (PALI) | United States | $0.275B | -11.41 |
| Invivyd, Inc. (IVVD) | United States | $0.270B | -2.42 |
| Inhibikase Therapeutics, Inc. (IKT) | United States | $0.296B | -4.44 |
| X4 Pharmaceuticals, Inc (XFOR) | United States | $0.297B | -4.99 |
| SUTRO BIOPHARMA, INC. (STRO) | United States | $0.260B | -3.05 |
| SAB Biotherapeutics, Inc. (SABS) | United States | $0.306B | -25.49 |
| Century Therapeutics, Inc. (IPSC) | United States | $0.306B | -4.02 |
| Lineage Cell Therapeutics, Inc. (LCTX) | United States | $0.241B | -10.35 |